KRAS 시장 : 업계 동향과 세계 예측 - 적응증별, 분자 유형별, 치료 유형별, 투여 경로별, 주요 지역별

GLOBAL KRAS MARKET: OVERVIEW

As per Roots Analysis, the global KRAS market valued at USD 73 million in the current year is expected to grow at a CAGR of 53.6% during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Indication

• Acute Myeloid Leukemia
• Colorectal Cancer
• Head and Neck Cancer
• Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Phelan-McDermid Syndrome
• Skin Cancer

Type of Molecule

• Biologic
• Small Molecule

Type of Therapy

• Monotherapy
• Combination Therapy

Route of Administration

• Intravenous
• Intramuscular
• Intradermal
• Intraocular
• Intraperitoneal
• Oral
• Subcutaneous

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

GLOBAL KRAS MARKET: GROWTH AND TRENDS

Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5 million across the globe, by 2040. A major factor contributing to the high mortality rate associated with this condition is the tendency for late diagnosis, which in turn delays treatment and significantly reduces the patient's chances of survival.

Given that conventional therapies have been unable to exhibit significant efficacy in the treatment of RAS mutated cancers, novel drugs, specifically targeting the RAS gene, have emerged as a promising alternative. In fact, drug developers in this field are increasingly focusing on creating therapies that target specific oncogenic mutations primarily responsible for the onset and progression of the disease. Notably, RAS which was once considered to be an undruggable target, has been linked to 30% of human cancer. Over the years, numerous drug candidates have been investigated to specifically target RAS-mutated genes. Additionally, driven by encouraging clinical trial results, substantial financial assistance, and growing demand for targeted therapeutic modalities, the RAS targeting therapies market is anticipated to witness steady growth over the next decade

GLOBAL KRAS MARKET: KEY INSIGHTS

The report delves into the current state of global KRAS market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Presently, several companies claim to be engaged in the development of novel drug candidates for the treatment of various cancers originating due to RAS mutations.
• Most of the drug candidates are being evaluated in early stages of development, either as monotherapies or in combination with other products, for delivery via different administration routes.
• Over 70% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the RAS targeting therapies (79%) are designed for administration via the oral route.

• In pursuit of gaining a competitive edge, firms located in different regions are actively investing, in terms of both resources and capital, to conduct R&D of their proprietary products.
• Over the years, there has been significant increase in number of clinical trials related to this novel class of therapies, across different geographies.
• Clinical research activity, in terms of the number of trials registered, is reported to have increased at a CAGR of 5%, in the past three years. Of the total number of trials, close to 25% of the studies have already been completed, while 60% are active and still recruiting patients.
• In recent years, a large number of companies have recently entered into strategic collaborations for the development of novel small molecule candidates.
• Majority of the deals were reported to be product licensing agreements, representing over 30% of the total number of instances.
• Foreseeing lucrative returns, many public and private investors have made investments across several funding rounds, in the last five years.
• Of the total, close to USD 600 million was raised through venture capital financing, representing around 40% of the overall share. On the other hand, over 5 instances of IPOs / secondary offerings were reported, wherein players collectively raised more than USD 775 million in financing.
• Both industry players and academic institutes have made significant contributions towards expanding the pool of published scientific literature; past and ongoing studies were focused on treatment of cancer indications.
• Majority of the authors affiliated with deemed universities have published articles focused on KRAS (80%), in the last year.
• In the past years, there has been an exponential increase in the number of publications, including research articles focused on RAS targeting therapies.
• Published articles / papers indicate that the current research activity is focused on targeting RAS isoforms, primarily mutated KRAS gene.
• Majority of the publications are focused on RAS targeting therapies intended for colorectal cancer, lung cancer and pancreatic cancer.
• In order to adequately monetize their proprietary offerings, drug developers are actively exploring diverse commercialization strategies across various stages of a product's launch cycle.
• Driven by the growing cancer burden and rising need for targeted drug therapies, the RAS targeted therapies market is projected to grow at a lucrative rate over the coming decade.
• The overall market opportunity is likely to be distributed across different types of therapies and routes of administration.

Example Players in the KRAS Market

• Amgen
• GlobeImmune
• Jacobio Pharmaceuticals
• Mirati Therapeutics
• Novartis
• Onconova Therapeutics
• Targovax
• Verastem Oncology.

GLOBAL KRAS MARKET

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global KRAS market, focusing on key market segments, including [A] type of indication, [B] type of molecule, [C] type of therapy, [D] route of administration and [E] key geographical regions.
• Market Landscape: A comprehensive evaluation of RAS targeting therapies, considering various parameters, such as [A] current status of development, [B] phase of development, [C] type of molecule, [D] type of therapy, [E] target therapeutic area, [F] target gene, [G] line of treatment and [H] route of administration. Additionally, the section includes a comprehensive evaluation of companies engaged in the development of RAS targeting therapies, based on several relevant parameters, such as [A] year of establishment, [B] employee count and [C] geographical presence.
• Clinical Trial Analysis: An in-depth analysis of clinical trials of various RAS targeting therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] enrolled patient population, [E] study design, [F] leading industry sponsors / collaborators, [G] trial focus, [H] target indication, [I] most popular indications and [J] regional distribution of trials.
• Product Competitiveness Analysis: An insightful competitive analysis of key players engaged in KRAS market (on the basis of the strength of their respective development portfolios), examining factors, such as [A] company size and [B] stage of development of lead molecules.
• Company Profiles: In-depth profiles of companies engaged in offering RAS targeting therapies, focusing on [A] company overview, [B] product portfolio and [C] recent developments and an informed future outlook.
• Publication Analysis: A comprehensive analysis of close to 1,600 peer-reviewed scientific articles related to research on RAS targeting therapies, based on [A] year of publication, [B] focus areas, [C] type of molecule, [D] popular keywords and [E] key journals.
• Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in this domain, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] most active players (in terms of the number of partnerships signed) and [E] geographical distribution of partnership activity.
• Funding and Investments: An in-depth analysis of various investments, such as [A] venture capital financing, [B] debt financing, [C] grants / awards, [D] capital raised from IPOs and [E] subsequent offerings that were undertaken by players engaged in KRAS market.
• Key Commercialization Strategies: A detailed discussion on the various commercialization strategies that have been adopted by drug developers engaged in KRAS market across different stages of therapy development, including pre-drug launch, at / during drug launch and post-marketing stage.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Research Methodology
  • 1.2.1. Research Assumptions
  • 1.2.2. Project Methodology
  • 1.2.3. Forecast Methodology
  • 1.2.4. Robust Quality Control
  • 1.2.5. Key Considerations
    • 1.2.5.1. Demographics
    • 1.2.5.2. Economic Factors
    • 1.2.5.3. Government Regulations
    • 1.2.5.4. Supply Chain
    • 1.2.5.5. COVID Impact / Related Factors
    • 1.2.5.6. Market Access
    • 1.2.5.7. Healthcare Policies
    • 1.2.5.8. Industry Consolidation
• 1.3 Key Questions Answered
• 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Overview of RAS Targeting Therapies
• 3.2. Approaches Used to Target Mutated RAS Gene
• 3.3. Historical Notable Developments
• 3.4. Prominent Gene Driver Related Mutations in RAS Mutated Cancers
• 3.5. Challenges and Future Perspectives Associated with Treatment of RAS Mutated Cancers

4. CURRENT MARKET LANDSCAPE

• 4.1. RAS Targeting Therapies: Pipeline Review
  • 4.1.1. Analysis by Phase of Development
  • 4.1.2. Analysis by Route of Administration
  • 4.1.3. Analysis by Line of Treatment
  • 4.1.4. Analysis by Type of Therapy
  • 4.1.5. Analysis by Type of Molecule
  • 4.1.6. Analysis by Target Gene
  • 4.1.7. Analysis by Target Therapeutic Area
  • 4.1.8. Analysis by Phase of Development and Leading Players
• 4.2. RAS Targeting Therapies: Developer Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Geography

5. CLINICAL TRIALS AND ENDPOINT ANALYSIS

• 5.1. RAS Targeting Therapies: List of Clinical Trials
  • 5.1.1. Analysis by Trial Status
  • 5.1.2. Analysis by Trial Registration Year
  • 5.1.3. Analysis by Type of Masking
  • 5.1.4. Analysis by Type of Intervention Model
  • 5.1.5. Analysis by Study Design
  • 5.1.6. Analysis by Type of Sponsor
  • 5.1.7. Most Active Players: Analysis by Number of Trials Registered
  • 5.1.8. Analysis by Trial Registration Year and Geography
  • 5.1.9. Analysis by Type of Target Indication
  • 5.1.10. Analysis by Enrolled Patient Population
  • 5.1.11. Analysis of Enrolled Patient Population by Geography
  • 5.1.12. Analysis of Number of Clinical Trials by Geography

6. PRODUCT COMPETITIVENESS ANALYSIS

• 6.1. Product Competitiveness: North America
• 6.2. Product Competitiveness: Europe
• 6.3. Product Competitiveness: Asia-Pacific

7. COMPANY PROFILES

• 7.1. Amgen
  • 7.1.1. Company Overview
  • 7.1.2. Financial Information
  • 7.1.3. Portfolio of RAS Targeting Therapies
  • 7.1.4. Recent Developments and Future Outlook
• 7.2. GlobeImmune
  • 7.2.1. Company Overview
  • 7.2.2. Financial Information
  • 7.2.3. Portfolio of RAS Targeting Therapies
  • 7.2.4. Recent Developments and Future Outlook
• 7.3. Jacobio Pharmaceuticals
  • 7.3.1. Company Overview
  • 7.3.2. Financial Information
  • 7.3.3. Portfolio of RAS Targeting Therapies
  • 7.3.4. Recent Developments and Future Outlook
• 7.4. Mirati Therapeutics
  • 7.4.1. Company Overview
  • 7.4.2. Financial Information
  • 7.4.3. Portfolio of RAS Targeting Therapies
  • 7.4.4. Recent Developments and Future Outlook
• 7.5. Novartis
  • 7.5.1. Company Overview
  • 7.5.2. Financial Information
  • 7.5.3. Portfolio of RAS Targeting Therapies
  • 7.5.4. Recent Developments and Future Outlook
• 7.6. Onconova Therapeutics
  • 7.6.1. Company Overview
  • 7.6.2. Financial Information
  • 7.6.3. Portfolio of RAS Targeting Therapies
  • 7.6.4. Recent Developments and Future Outlook
• 7.7. Targovax
  • 7.7.1. Company Overview
  • 7.7.2. Financial Information
  • 7.7.3. Portfolio of RAS Targeting Therapies
  • 7.7.4. Recent Developments and Future Outlook
• 7.8. Verastem Oncology
  • 7.8.1. Company Overview
  • 7.8.2. Financial Information
  • 7.8.3. Portfolio of RAS Targeting Therapies
  • 7.8.4. Recent Developments and Future Outlook

8. PUBLICATION ANALYSIS

• 8.1. RAS Targeting Therapies: Recent Publications
  • 8.1.1. Analysis by Year of Publication
  • 8.1.2. Analysis by Type of Publication
  • 8.1.3. Analysis by Study Objective
  • 8.1.4. Analysis by Emerging Focus Areas
  • 8.1.5. Analysis by Target Therapeutic Area
  • 8.1.6. Analysis by Target Gene
  • 8.1.7. Analysis by Target Indication
  • 8.1.8. Analysis by Affiliation of First Author
  • 8.1.9. Leading Players: Analysis by Number of Publications
  • 8.1.10. Key Journals: Analysis by Number of Publications

9. PARTNERHSIPS AND COLLABORATIONS

• 9.1. RAS Targeting Therapies: List of Partnerships and Collaborations
  • 9.1.1. Analysis by Year of Partnership
  • 9.1.2. Analysis by Type of Partnership
  • 9.1.3. Analysis by Type of Partner
  • 9.1.4. Analysis by Type of Molecule
  • 9.1.5. Most Active Players: Analysis by Number of Partnerships
  • 9.1.6. Most Active Partners: Analysis by Number of Partnerships
  • 9.1.7. Regional Analysis
  • 9.1.8. Intercontinental and Intracontinental Agreements

10. FUNDING AND INVESTMENT ANALYSIS

• 10.1. RAS Targeting Therapies: Funding and Investments
  • 10.1.1. Analysis by Number of Funding Instances
  • 10.1.2. Analysis by Amount Invested
  • 10.1.3. Analysis by Type of Funding
  • 10.1.4. Most Active Players: Analysis by Amount Raised
  • 10.1.5. Most Active Investors: Analysis by Number of Instances
  • 10.1.6. Analysis by Geography

11. KEY COMMERCIALIZATION STRATEGIES

• 11.1. Successful Drug Launch Strategy: ROOTS Framework
• 11.2. Successful Drug Launch Strategy: Product Differentiation
• 11.3. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
• 11.4. Key Commercialization Strategies Adopted by Companies Focused on RAS Targeting Therapies
  • 11.4.1. Strategies Adopted Before Therapy Approval
• 11.5. Strategies Adopted During / Post Therapy Approval
• 11.6. Analysis by Ease of Implementation, Value Addition and Current Adoption (Harvey Ball Framework)

12. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 12.1. Forecast Methodology and Key Assumptions
• 12.2. Global RAS Targeting Therapies Market, Till 2035
• 12.3. Global RAS Targeting Therapies Market, Till 2035: Distribution by Target Indication
• 12.4. Global RAS Targeting Therapies Market, Till 2035: Distribution by Type of Molecule
• 12.5. Global RAS Targeting Therapies Market, Till 2035: Distribution by Type of Therapy
• 12.6. Global RAS Targeting Therapies Market, Till 2035: Distribution by Route of Administration
• 12.7. Global RAS Targeting Therapies Market, Till 2035: Distribution by Geography
• 12.8. RAS Targeting Therapies: Individual Product Sales Forecasts
  • 12.8.1. LUMAKRASTM (Amgen): Sales Forecast
  • 12.8.2. Adagrasib (Mirati Therapeutics): Sales Forecast
  • 12.8.3. AMO-01 (AMO Pharma): Sales Forecast
  • 12.8.4. Antroquinonol (Golden Biotech): Sales Forecast
  • 12.8.5. Binimetinib (Array Biopharma): Sales Forecast
  • 12.8.6. CH7126766/VS6766 (Verastem Oncology): Sales Forecast
  • 12.8.7. LXH274 (Novartis): Sales Forecast
  • 12.8.8. Rigosertib (Onconova Therapeutics): Sales Forecast
  • 12.8.9. RMC-4630 (Revolution Medicine): Sales Forecast
  • 12.8.10. TG01 (Targovax): Sales Forecast
  • 12.8.11. Tipifarnib (Kura Oncology): Sales Forecast
  • 12.8.12. siG12D (Silenseed): Sales Forecast

13. CONCLUSION

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS